- Home
- PCM vs RNXT Comparison
PCM vs RNXT Comparison
Compare PCM & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCM | RNXT |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 79.4M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PCM | RNXT |
|---|---|---|
| Price | $4.89 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 68.9K | ★ 378.0K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $243.48 |
| Revenue Next Year | N/A | $196.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $4.83 | $0.73 |
| 52 Week High | $6.29 | $2.59 |
Technical Indicators
Market Signals| Indicator | PCM | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 34.84 |
| Support Level | $4.85 | $0.83 |
| Resistance Level | $5.83 | $1.51 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 5.00 | 24.63 |
Price Performance
Historical ComparisonAbout PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.